Mantle cell lymphoma in the orbital and adnexal region

Peter Kristian Rasmussen; L D Sjö; J U Prause; E Ralfkiaer; S Heegaard

doi:10.1136/bjo.2008.146910

Mantle cell lymphoma in the orbital and adnexal region

Peter Kristian Rasmussen, L D Sjö, J U Prause, E Ralfkiaer, S Heegaard

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

57 Citationer (Scopus)

Abstract

Udgivelsesdato: 2009-Aug

Originalsprog	Engelsk
Tidsskrift	British Journal of Ophthalmology
Vol/bind	93
Udgave nummer	8
Sider (fra-til)	1047-51
Antal sider	4
ISSN	0007-1161
DOI	https://doi.org/10.1136/bjo.2008.146910
Status	Udgivet - 2009

Bibliografisk note

Keywords: Aged; Aged, 80 and over; Eye Neoplasms; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Orbital Neoplasms; Prognosis; Survival Analysis; Treatment Outcome

Adgang til dokumentet

10.1136/bjo.2008.146910

Citationsformater

@article{d2611f8088db11df928f000ea68e967b,

title = "Mantle cell lymphoma in the orbital and adnexal region",

abstract = "AIMS: To characterise clinicopathological features of mantle cell lymphoma (MCL) in the orbital and adnexal region. METHODS: Data on lymphoid lesions were retrieved searching the Danish Ocular Lymphoma Database 1980-2005. Specimens were collected from Danish pathological departments and re-evaluated with a panel of monoclonal antibodies. For all patients with confirmed MCL the complete clinical files were collected and reviewed. RESULTS: Twenty-one patients with MCL in the orbital and adnexal region were identified comprising 9% (21/230) of all lymphoma in the ocular region. There were 18 male patients and three female patients with an age range from 60 to 90 years (median 75 years). Orbital and adnexal region MCL as first presenting symptom comprised 67% of the patients. Of these, 71% had bilateral involvement. The orbit (71%) and eyelids (64%) were the most commonly affected sites. All but two presented in stage III/IV. Secondary MCL comprised 33% of the patients. Bilateral affection (29%) was less common in this patient group. The median survival was not different between the two presentation groups. Patients receiving anti-CD20 (rituximab)-containing chemotherapy had a significantly better 5-year overall survival (OS) rate (83%) than patients in treatment regimes without rituximab (5-year OS rate, 8%). CONCLUSIONS: Orbital and adnexal region MCL presents in elderly males. The orbit and eyelid are frequently involved. There is a very high proportion of systemic involvement in general with MCL of the orbital and adnexal region. Most patients presented with stage IV disease and had multiple relapses and short survival time. Treatment with rituximab-containing chemotherapy improved survival significantly compared with combination chemotherapy without rituximab.",

author = "Rasmussen, {Peter Kristian} and Sj{\"o}, {L D} and Prause, {J U} and E Ralfkiaer and S Heegaard",

note = "Keywords: Aged; Aged, 80 and over; Eye Neoplasms; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Orbital Neoplasms; Prognosis; Survival Analysis; Treatment Outcome",

year = "2009",

doi = "10.1136/bjo.2008.146910",

language = "English",

volume = "93",

pages = "1047--51",

journal = "British Journal of Ophthalmology",

issn = "0007-1161",

publisher = "B M J Group",

number = "8",

}

TY - JOUR

T1 - Mantle cell lymphoma in the orbital and adnexal region

AU - Rasmussen, Peter Kristian

AU - Sjö, L D

AU - Prause, J U

AU - Ralfkiaer, E

AU - Heegaard, S

N1 - Keywords: Aged; Aged, 80 and over; Eye Neoplasms; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Orbital Neoplasms; Prognosis; Survival Analysis; Treatment Outcome

PY - 2009

Y1 - 2009

N2 - AIMS: To characterise clinicopathological features of mantle cell lymphoma (MCL) in the orbital and adnexal region. METHODS: Data on lymphoid lesions were retrieved searching the Danish Ocular Lymphoma Database 1980-2005. Specimens were collected from Danish pathological departments and re-evaluated with a panel of monoclonal antibodies. For all patients with confirmed MCL the complete clinical files were collected and reviewed. RESULTS: Twenty-one patients with MCL in the orbital and adnexal region were identified comprising 9% (21/230) of all lymphoma in the ocular region. There were 18 male patients and three female patients with an age range from 60 to 90 years (median 75 years). Orbital and adnexal region MCL as first presenting symptom comprised 67% of the patients. Of these, 71% had bilateral involvement. The orbit (71%) and eyelids (64%) were the most commonly affected sites. All but two presented in stage III/IV. Secondary MCL comprised 33% of the patients. Bilateral affection (29%) was less common in this patient group. The median survival was not different between the two presentation groups. Patients receiving anti-CD20 (rituximab)-containing chemotherapy had a significantly better 5-year overall survival (OS) rate (83%) than patients in treatment regimes without rituximab (5-year OS rate, 8%). CONCLUSIONS: Orbital and adnexal region MCL presents in elderly males. The orbit and eyelid are frequently involved. There is a very high proportion of systemic involvement in general with MCL of the orbital and adnexal region. Most patients presented with stage IV disease and had multiple relapses and short survival time. Treatment with rituximab-containing chemotherapy improved survival significantly compared with combination chemotherapy without rituximab.

AB - AIMS: To characterise clinicopathological features of mantle cell lymphoma (MCL) in the orbital and adnexal region. METHODS: Data on lymphoid lesions were retrieved searching the Danish Ocular Lymphoma Database 1980-2005. Specimens were collected from Danish pathological departments and re-evaluated with a panel of monoclonal antibodies. For all patients with confirmed MCL the complete clinical files were collected and reviewed. RESULTS: Twenty-one patients with MCL in the orbital and adnexal region were identified comprising 9% (21/230) of all lymphoma in the ocular region. There were 18 male patients and three female patients with an age range from 60 to 90 years (median 75 years). Orbital and adnexal region MCL as first presenting symptom comprised 67% of the patients. Of these, 71% had bilateral involvement. The orbit (71%) and eyelids (64%) were the most commonly affected sites. All but two presented in stage III/IV. Secondary MCL comprised 33% of the patients. Bilateral affection (29%) was less common in this patient group. The median survival was not different between the two presentation groups. Patients receiving anti-CD20 (rituximab)-containing chemotherapy had a significantly better 5-year overall survival (OS) rate (83%) than patients in treatment regimes without rituximab (5-year OS rate, 8%). CONCLUSIONS: Orbital and adnexal region MCL presents in elderly males. The orbit and eyelid are frequently involved. There is a very high proportion of systemic involvement in general with MCL of the orbital and adnexal region. Most patients presented with stage IV disease and had multiple relapses and short survival time. Treatment with rituximab-containing chemotherapy improved survival significantly compared with combination chemotherapy without rituximab.

U2 - 10.1136/bjo.2008.146910

DO - 10.1136/bjo.2008.146910

M3 - Journal article

C2 - 19429588

SN - 0007-1161

VL - 93

SP - 1047

EP - 1051

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

IS - 8

ER -